Abstract: The invention relates to a group of isolated polypeptides and derivatives that can bind genetically to immunoglobulins or antibodies. The invention also relates to industrial and other applications of these molecules, e.g., antibody purifications.

Abstract: Methods for Identifying protein modulators of eukaryotic cells by expressing a combinatorial library of potential agonists inside a eukaryotic cell and then directly selecting for an agonist of a target molecule. Some methods involve co-culturing a cell expressing a combinatorial library of potential agonists and a second cell, and then selecting agents that modulate a phenotype of or a desired cellular response in the second cell. Preferably, the agonists are antibodies introduced into and expressed in the starting cells, such as agonist anti-EpoR, anti-TpoR, or G-CSFR antibodies. Also disclosed are methods for selecting from combinatorial antibody libraries bispecific antibodies that can regulate cell phenotypes.

Abstract: Provided herein methods of alleviating the symptoms of multiple myeloma in a patient or subject in need thereof, methods of treating multiple myeloma in a patient or subject, and methods of preventing development of multiple myeloma in a patient at risk thereof, such as a patient with monoclonal gammopathy of undetermined significance (MGUS), which methods include administering an agent effective to treat a Mycoplasma infection. The invention also relates to a new class of antigen, MG281 protein {also referenced as Protein M), that binds to various immunoglobulins with high affinity, and their uses in purifying immunoglobulins. The invention additionally relates to using MG281 protein and analog or derivative molecules for treating autoimmune diseases. Further provided are antigens and antibodies for use in the disclosed methods, and the identification of molecules that bind to MG281 protein.

Abstract: Methods for Identifying protein modulators of eukaryotic cells by expressing a combinatorial library of potential agonists inside a eukaryotic cell and then directly selecting for an agonist of a target molecule. Some methods involve co-culturing a cell expressing a combinatorial library of potential agonists and a second cell, and then selecting agents that modulate a phenotype of or a desired cellular response in the second cell. Preferably, the agonists are antibodies introduced into and expressed in the starting cells, such as agonist anti-EpoR, anti-TpoR, or G-CSFR antibodies. Also disclosed are methods for selecting from combinatorial antibody libraries bispecific antibodies that can regulate cell phenotypes.

Abstract: Provided herein methods of alleviating the symptoms of multiple myeloma in a patient or subject in need thereof, methods of treating multiple myeloma in a patient or subject, and methods of preventing development of multiple myeloma in a patient at risk thereof, such as a patient with monoclonal gammopathy of undetermined significance (MGUS), which methods include administering an agent effective to treat a Mycoplasma infection. The invention also relates to a new class of antigen, MG281 protein {also referenced as Protein M), that binds to various immunoglobulins with high affinity, and their uses in purifying immunoglobulins. The invention additionally relates to using MG281 protein and analog or derivative molecules for treating autoimmune diseases. Further provided are antigens and antibodies for use in the disclosed methods, and the identification of molecules that bind to MG281 protein.

Abstract: The invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving 5-HT2A receptor, serotonin transporter (SERT) and/or pathways involving dopamine D2 receptor signaling systems.

Abstract: The present invention relates to a method for isolating from the immunological gene repertoire a gene coding for a receptor having the ability to bind a preselected ligand. Receptors produced by the gene isolated by the method, particularly catalytic receptors, are also contemplated.

Abstract: The present invention comprises methods and compositions for producing and/or enhancing an immunological response in a subject against a target moiety such as a disease-related moiety by administration of an antigenic version of the target moiety having one or more unnatural amino acid and/or by administration of an antibody against a version of a target moiety having one or more unnatural amino acid which antibody is cross reactive with the natural target moiety.

Abstract: The present invention provides antibody targeting compounds in which the specificity of the antibody has been reprogrammed by covalently or noncovalently linking a targeting agent to the combining site of an antibody. By this approach, the covalently modified antibody takes on the binding specificity of the targeting agent. The compound may have biological activity provided by the targeting agent or by a separate biological agent. Various uses of the invention compounds are provided.

Abstract: A composition of matter which comprises a non-gaseous nitrogen containing compound; and a spore of a micro-organism. A method of determining a source of a material the material being an explosive or a substance used in the preparation of the explosive, the material comprises a spore of a micro-organism uniquely associated with the material, the method comprises inducing the spore to transform into a vegetative micro-organism and identifying the micro-organism as being associated with the material, thereby determining the source of the material.

Abstract: Filamentous phage comprising a matrix of cpVIII proteins encapsulating a genome encoding first and second polypeptides of an antogenously assembling receptor, such as an antibody, and a receptor comprised of the first and second polypeptides surface-integrated into the matrix via a filamentous phage coat protein membrane anchor domain fused to at least one of the polypeptides.

Abstract: The present invention comprises methods and compositions for producing and/or enhancing an immunological response in a subject against a target moiety such as a disease-related moiety by administration of an antigenic version of the target moiety having one or more unnatural amino acid and/or by administration of an antibody against a version of a target moiety having one or more unnatural amino acid which antibody is cross reactive with the natural target moiety.

Abstract: The present invention relates to a method for isolating from the immunological gene repertoire a gene coding for a receptor having the ability to bind a preselected ligand. Receptors produced by the gene isolated by the method, particularly catalytic receptors, are also contemplated.

Abstract: The present invention provides methods for identifying cognate binding pairs from two libraries of biomolecules (e.g., polypeptides). The methods typically involve displaying a first library of candidate biomolecules (e.g., receptors or epitopes) on a first replicable genetic package (e.g., a cell surface display platform) and displaying a second library of candidate biomolecules (e.g., ligands) on a second replicable genetic package (e.g., a phage display platform), contacting the first library with the second library, and then selecting members of the first library to which a member of the second library is bound. Also provided in the invention are compositions and kits for carrying out the methods of the invention.

Abstract: The present invention provides methods for identifying cognate binding pairs from two libraries of biomolecules (e.g., polypeptides). The methods typically involve displaying a first library of candidate biomolecules (e.g., receptors or epitopes) on a first replicable genetic package (e.g., a cell surface display platform) and displaying a second library of candidate biomolecules (e.g., ligands) on a second replicable genetic package (e.g., a phage display platform), contacting the first library with the second library, and then selecting members of the first library to which a member of the second library is bound. Also provided in the invention are compositions and kits for carrying out the methods of the invention.

Abstract: Nine efficient aldolase antibodies were generated using hapten 2. This hapten combines, in a single molecule, structural components employed for reactive immunization with structural components employed for forming a transition state analog of the aldol reaction. Characterization of two of these antibodies reveals that they are highly proficient (up to 1000-fold better than any other antibody catalyst) and enantioselective catalysts for aldol and retro-aldol reactions and exhibit enantio- and diastereo-selectivities opposite that of antibody 38C2.

Abstract: The present invention comprises methods and compositions for producing and/or enhancing an immunological response in a subject against a target moiety such as a disease-related moiety by administration of an antigenic version of the target moiety having one or more unnatural amino acid and/or by administration of an antibody against a version of a target moiety having one or more unnatural amino acid which antibody is cross reactive with the natural target moiety.

Abstract: The present invention discloses a system for the anonymous purchase of goods. A Customer requests to purchase some physical goods, the Vendor determines the cost of the goods, and asks the Customer to select a Carrier. The Vendor requests a Customer Token and redirects the Customer's browser to the Carrier, with the Customer Token, a Vendor Token and a description of the package. The Carrier validates the Vendor's Token and uses the Customer's token to request information about the Customer, including shipping instructions. The Carrier assigns a shipping identifier and shipping cost and redirects the Customer's browser back to the Vendor along with the identifier and shipping cost. The Vendor adjusts the cost to include shipping, packages the goods, and labels the packages with the shipping identifier. The Carrier picks up the packages, prints a complete label using the Customer information associated with the shipping identifier and delivers the goods.

Abstract: The present invention discloses a system for the anonymous purchase of goods. A Customer requests to purchase some physical goods, the Vendor determines the cost of the goods, and asks the Customer to select a Carrier. The Vendor requests a Customer Token and redirects the Customer's browser to the Carrier, with the Customer Token, a Vendor Token and a description of the package. The Carrier validates the Vendor's Token and uses the Customer's token to request information about the Customer, including shipping instructions. The Carrier assigns a shipping identifier and shipping cost and redirects the Customer's browser back to the Vendor along with the identifier and shipping cost. The Vendor adjusts the cost to include shipping, packages the goods, and labels the packages with the shipping identifier. The Carrier picks up the packages, prints a complete label using the Customer information associated with the shipping identifier and delivers the goods.

Abstract: The present invention is directed to methods for formation of a chemically programmed antibody comprising the steps of: (1) reacting a conjugate comprising a signal module covalently linked to a proadapter with a catalytic moiety selected from the group consisting of a catalytic antibody and a Fab fragment of a catalytic antibody, wherein the proadapter includes therein a precursor to a reactive moiety activated to a reactive moiety by a reaction catalyzed by the catalytic moiety; and (2) crosslinking the reactive moiety to a side chain of an amino acid residue in the active site of the catalytic moiety to produce the chemically programmed antibody. The invention also encompasses chemically programmed antibodies formed by these methods, methods for their use, and pharmaceutical compositions, as well as proadaptors and conjugates including them. Chemically programmed antibodies are useful for the treatment of cancer, particularly in metastasis.